The Ozempic economy

Republicans are stoking anti-Muslim sentiment in new ways ahead of the midterms. This episode was produced by Avishay Artsy and Danielle Hewitt, edited by Amina Al-Sadi, fact-checked by Peter Balonon-Rosen and Ariana Aspuru, engineered by Bridger Dunnagan and David Tatasciore, an ...  Show more

People are getting tired of the dating apps and turning to a more old-fashioned way of finding love. This episode was produced by Kelli Wessinger and Ariana Aspuru, edited by Amina Al-Sadi, fact-checked by Melissa Hirsch, engineered by Bridger Dunnagan, and hosted by Jonquilyn Hi ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...